Oncotalks hematology videos and news

ESMO 2019 Philippe Saiag, MD, PhD; Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study​

Philippe Saiag, MD, PhD from the University of Versailles-SQY, Versailles, France is commenting on the abstract: 1338P - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study

Related items

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Valentina Guarneri, MD, PhD from the University of Padua, Padua, Italy is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
ESMO , Kisqali Channel , Latvia , Lithuania , Estonia , Hungary , Albania
00:03:29
ESMO 2019 Conleth Murphy, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Conleth Murphy, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Conleth Murphy, MD, PhD from the Bon Secours Cork Cancer Centre, Cork, Ireland is commenting on the abstract LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
ESMO , Kisqali Channel , Hungary , Lithuania , Albania
00:03:01
ESMO 2019 prof. Sherko Kümmel, MD; LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 prof. Sherko Kümmel, MD; LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial

prof. Sherko Kümmel, MD from the Kliniken Essen-Mitte, Essen, Germany is commenting on the abstract LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
ESMO , Hungary , Lithuania , Albania , Slovenia
00:02:45
ASCO 2019 Prof. Dirk Schadendorf, MD

ASCO 2019 Prof. Dirk Schadendorf, MD

Prof. Dirk Schadendorf, MD from the University Hospital Essen, Germany is commenting on his abstract that was presented at ASCO 2019 in ChicagoSchadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). J Clin Oncol 37, 2019 (suppl; abstr 9582)
ASCO , Latvia , Lithuania , Estonia , Hungary , Albania
00:10:57